Member Info for Sharedealer2019

Art your mum says come home your making yourself look like a fool!

More news to come

.

.

AUC1 exactly! That’s confidence for you!

AND I repeat no one is keeping you here so FO!

ART anyone can read your posting history and perhaps should!

That’s the beauty of this site, history can be read!

This is the second JV with two different multi £billion companies, for a small company that is exceptionally good work!

If two £billion companies believe in TYM perhaps you should too!

Art your subtle deramping is really getting boring now!

Patrick Cheetham, Executive Chairman of Tertiary Minerals plc said:

"First Quantum is strongly motivated to find additional ore feed for Sentinel and, at Mukai, we have defined a priority soil anomaly along strike from copper mineralisation already drilled by First Quantum on its adjacent Tirosa Prospect.

"If exploration is successful, we stand to benefit from First Quantum's US$2.1 billion investment in the Trident operations and the joint venture earn-in terms have been tied to specific mineral resource and mining decision milestones, rather than specific exploration expenditures. The bar is set high, consistent with the large size of the Sentinel mining operation and the agreed terms require First Quantum to define a copper resource with an in-ground value of over US$700 million at today's copper price, before it earns any interest in the project.

"Evaluating the potential at Mukai is important for the parties and for Zambia given its proximity to the infrastructure already established at Trident. First Quantum is the natural partner for this undertaking given their unrivalled track record of recognising opportunities, defining resources, and developing projects quickly and cost effectively."

Great news! More ducks lining up!

Lots still going on in the background.

Some may have missed but there has been a steady buyer today who has been purchasing 500,000 shares at a time

Which would also add up, new co don’t need a CEO, that can be brought in. Chief scientific officer who has developed the product and has all the technical knowledge, VERY hard to replicate by a newbie coming in.

Come on people, join the dots….

This share is a great investment over a few years and will bring those investors great rewards.

If your a trader be that new or old….perhaps you should read this…

‘ Around 1% – 20% of traders earn a profitable margin at the end of the day. The low success rate often discourages the newbies who learn new ways from an online course or television. Studies have shown that around 97% of day traders have lost their money in two years.’

Stop trading, START INVESTING!

Company buying them out have their own CEO and decided it was better that he went.

That’s the press release in 2 months time

Thanks PEEL you helped with another cheap top up

‘ Dr Gino Miele, Chief Scientific Officer, genedrive plc, said: "The collaboration of our company with the research and clinical team at MFT is a shining example of the NHS collaborating with a commercial company, from early product development through to clinical validation in real-world settings, to deliver real improvements in patient outcomes in a cost-effective way. We are delighted with the positive recommendation from NICE and the success of the multi-disciplinary team collaboration under DEVOTE. We look forward to our CYP2C19 ID kit, the second point of care pharmacogenetic test developed in collaboration with this team for NHS use, being made available for the benefit of patients who have suffered a stroke or TIA." ’

Perhaps another reason they moved Gino to CEO is that he did all the work up to the NICE recommendation, therefore he was the best to take it to market!

Professor you have always been a trader and shorter on LSE for any share you are in. Never listen to a word you say. When you have showed up the share price always increases!

Not desperate, am very pleased with the news :) :)

Sean you need someone who is able to converse with the Doctors, Consultants, Nurses etc that IS your Scientific personnel. Love how the derampers are trying to turn this amazingly positive news!!

Part of the takeover agreement perhaps ;)

The market should love this actually, Chief scientific officer moving to CEO, to then drive sales into other scientifically minded personnel within the NHS! FANTASTIC NEWS!